Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
The DOI matches its Crossref record; 74 of the 75 references it cites were found in a registry or an index.
Abstract
Maintaining research and development (R&D) productivity at a sustainable level is one of the main challenges currently facing the pharmaceutical industry. In this article, we discuss the results of a comprehensive longitudinal review of AstraZeneca's small-molecule drug projects from 2005 to 2010. The analysis allowed us to establish a framework based on the five most important technical determinants of project success and pipeline quality, which we describe as the five 'R's: the right target, the right patient, the right tissue, the right safety and the right commercial potential. A sixth factor - the right culture - is also crucial in encouraging effective decision-making based on these technical determinants. AstraZeneca is currently applying this framework to guide its R&D teams, and although it is too early to demonstrate whether this has improved the company's R&D productivity, we present our data and analysis here in the hope that it may assist the industry overall in addressing this key challenge.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is accumulating evidence that the success of candidate drugs is greatly enhanced if the drug target is independently confirmed by human genetic data.16, 17”
From Early Neurological Change After Ischemic Stroke Is Associated With 90-Day Outcome (2021) · cites this paper as [16]
In the citing paper
“Currently, techniques like structural magnetic resonance imaging (MRI), and molecular imaging of deposited Aβ and tau proteins using positron emission tomography (PET), are highly accurate in detecting the presence of pathophysiological and neuropathological changes of AD and are used in the drug development [10, 11].”
From Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer’s disease (2020) · cites this paper as [10]
In the citing paper
“In the past, other medical fields tried to address similar problems by increasing the volume of trials.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [106]
In the citing paper
“In reality, research and development costs increased while the number of drugs approved remained static106,107.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [106]
In the citing paper
“Early initiation of PK/PD assessment facilitates understanding of the biology by validating and confirming target engagement.50”
From Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development (2018) · cites this paper as [50]
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 4×
“Although clinical validation was not confirmed in the Phase IIa studies, retrospective analysis suggested that AZD1981 showed limited efficacy in an atopic/allergic asthma population selected by a positive skin prick test.”
BackgroundInfluentialInhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
Genomic responses in mouse models poorly mimic human inflammatory diseases
Seok, J., Warren, H. S., Cuenca, A. G., Mindrinos, M. N., Baker, H. V., Xu, W., Richards, D. R., McDonald-Smith, G. P., Gao, H., Hennessy, L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222878110 · Cited by 3,005 · cited 1×
“29 (13) Dose limited by compound characteristics or tissue exposure not established”
BackgroundPavord, I. D., Korn, S., Howarth, P., Bleecker, E. R., Buhl, R., Keene, O. N., Ortega, H., & Chanez, P. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60988-x · Cited by 2,221
Diagnosing the decline in pharmaceutical R&D efficiency
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981 · cited 1×
“11 (5) Evidence from previous phase not robust enough”
BackgroundLeckie, M. J., Brinke, A. T., Khan, J., Diamant, Z., O'Connor, B. J., Walls, C. M., Mathur, A. K., Cowley, H. C., Chung, K. F., Djukanovic, R., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03496-6 · Cited by 1,814
Lebrikizumab Treatment in Adults with Asthma
Corren, J., Lemanske, R. F., Hanania, N. A., Korenblat, P. E., Parsey, M. V., Arron, J. R., Harris, J. M., Scheerens, H., Wu, L. C., Su, Z., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106469 · Cited by 1,514
Research works printed but not linked: 3
- Herper, M. The truly staggering cost of inventing new drugs. Forbes [online] , (10 Feb 2012).
- Redfern, W. et al. Impact and frequency of different toxicities throughout the pharmaceutical life cycle. The Toxicologist 114, 231 (2010).
- Quirk, M. et al. Abstract P-09-045. Effects of low-trapping NMDA channel blocker AZD6765 on gamma-band EEG and psychotomimetic liability: a comparison to ketamine in freely behaving rats. Int. J. Neuropsychopharmacol. 15 (Suppl. S1), 153 (2012).
Cited by
Items 201–300 of 1,000
Whole-genome sequencing of half-a-million UK Biobank participantsPreprint
Li, S., Carss, K., Halldórsson, B. V., & Cortés, A. (2023) · medRxiv · doi:10.1101/2023.12.06.23299426 · Cited by 72
“There is consensus among the pharmaceutical industry that human genomic evidence increases the FDA approval rate at least 2-fold 81–84 .”
BackgroundYamamoto, Y., Välitalo, P. A. J., van den Berg, D., Hartman, R., van den Brink, W., Wong, Y. C., Huntjens, D. R. H., Proost, J. H., Vermeulen, A., Krauwinkel, W. J. J., et al. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-2065-3 · Cited by 74
“The primary reasons for attrition are safety issues (3).”
BackgroundExplainable Artificial Intelligence: A Perspective on Drug Discovery
Qadri, Y. A., Shaikh, S., Ahmad, K., Choi, I., Kim, S. W., & Vasilakos, A. V. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17091119 · Cited by 97
“The data obtained during the research process is combined into a translational approach to predict a clinically appropriate and effective dosage and regimen that ensures safety [11,12].”
Formalising recall by genotype as an efficient approach to detailed phenotyping and causal inference
Corbin, L. J., Tan, V. Y., Hughes, D. A., Wade, K. H., Paul, D. S., Tansey, K. E., Butcher, F., Dudbridge, F., Howson, J. M., Jallow, M. W., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03109-y · Cited by 70
Early Neurological Change After Ischemic Stroke Is Associated With 90-Day Outcome
Heitsch, L., Ibanez, L., Carrera, C., Binkley, M. M., Strbian, D., Tatlisumak, T., Bustamante, A., Ribó, M., Molina, C., Dávalos, A., et al. (2021) · Stroke · doi:10.1161/strokeaha.119.028687 · Cited by 70
The In Silico Drug Discovery Toolbox: Applications in Lead Discovery and Optimization
Bruno, A., Costantino, G., Sartori, L., & Radi, M. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867324666171107101035 · Cited by 78
Mohankumar, T., Chandramohan, V., Lalithamba, H. S., Jayaraj, R. L., Kumaradhas, P., Sivanandam, M., Hunday, G., Vijayakumar, R., Balakrishnan, R., Manimaran, D., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-57417-9 · Cited by 78
The Ascendance of Microphysiological Systems to Solve the Drug Testing Dilemma
Dehne, E.-M., Hasenberg, T., & Marx, U. (2017) · Future Science OA · doi:10.4155/fsoa-2017-0002 · Cited by 68
Genetic Insights for Drug Development in NAFLD
Eslam, M., & George, J. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.05.002 · Cited by 69
Mead, A. N., Amouzadeh, H. R., Chapman, K., Ewart, L., Giarola, A., Jackson, S. J., Jarvis, P., Jordaan, P., Redfern, W., Traebert, M., et al. (2016) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2016.05.002 · Cited by 67
Sanina, C., & Hare, J. M. (2015) · Circulation Research · doi:10.1161/circresaha.117.306306 · Cited by 70
Teng, M., & Gray, N. S. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.06.020 · Cited by 66
Refinement, Reduction, and Replacement of Animal Toxicity Tests by Computational Methods
Ford, K. A. (2016) · ILAR Journal · doi:10.1093/ilar/ilw031 · Cited by 72
“Toxicity accounts for up to 50% of failures in preclinical drug development (Cook et al. 2014; Kola and Landis 2004), indicating that there is a great need for rapid and reliable computational programs to assist in the prediction of toxicological events.”
BackgroundAchieving end-to-end success in the clinic: Pfizer’s learnings on R&D productivity
Fernando, K., Menon, S., Jansen, K. U., Naik, P., Nucci, G., Roberts, J., Wu, S. S., & Dolsten, M. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.12.010 · Cited by 69
Pointon, A., Pilling, J., Dorval, T., Wang, Y., Archer, C., & Pollard, C. (2017) · Toxicological Sciences · doi:10.1093/toxsci/kfw227 · Cited by 66
High-Throughput Cellular Thermal Shift Assays in Research and Drug Discovery
Henderson, M. J., Holbert, M. A., Simeonov, A. M., & Kallal, L. A. (2019) · SLAS DISCOVERY · doi:10.1177/2472555219877183 · Cited by 72
Ainslie, G. R., Davis, M., Ewart, L., Lieberman, L. A., Rowlands, D. J., Thorley, A. J., Yoder, G., & Ryan, A. M. (2019) · Lab on a Chip · doi:10.1039/c9lc00492k · Cited by 65
Kidney Organoids as Disease Models: Strengths, Weaknesses and Perspectives
Romero-Guevara, R., Ioannides, A., & Xinaris, C. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.563981 · Cited by 65
Targets for Drug Therapy for Autism Spectrum Disorder: Challenges and Future Directions
Lacivita, E., Perrone, R., Margari, L., & Leopoldo, M. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00965 · Cited by 78
Pharmaceutical and nutraceutical activation of FOXO3 for healthy longevity
McIntyre, R. L., Liu, Y. J., Hu, I. M., Morris, B. J., Willcox, B. J., Donlon, T. A., Houtkooper, R. H., & Janssens, G. E. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101621 · Cited by 70
Discontinued in 2013: oncology drugs
Williams, R. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.971154 · Cited by 69
“Demonstration of effective drug target engagement and expression of functional pharmacology not only illuminates mechanistic understanding but correlates with downstream success in drug development [3,4].”
BackgroundResultInfluentialGenetic-Driven Druggable Target Identification and Validation
Floris, M., Olla, S., Schlessinger, D., & Cucca, F. (2018) · Trends in Genetics · doi:10.1016/j.tig.2018.04.004 · Cited by 64
Human 3D Gastrointestinal Microtissue Barrier Function As a Predictor of Drug-Induced Diarrhea
Peters, M. F., Landry, T., Pin, C., Maratea, K., Dick, C., Wagoner, M. P., Choy, A. L., Barthlow, H. G., Snow, D., Stevens, Z., et al. (2018) · Toxicological Sciences · doi:10.1093/toxsci/kfy268 · Cited by 68
“gastrointestinal tract is presently among the target organs least likely to result in attrition in either the preclinical or clinical phases (Cook et al., 2014; Guengerich, 2011; Olson et al., 2000; Stevens and Baker, 2009).”
BackgroundInfluentialLong‐Term Electrical and Mechanical Function Monitoring of a Human‐on‐a‐Chip System
Oleaga, C., Lavado, A., Riu, A., Rothemund, S., Carmona‐Moran, C. A., Persaud, K., Yurko, A., Lear, J., Narasimhan, N. S., Long, C. J., et al. (2019) · Advanced Functional Materials · doi:10.1002/adfm.201805792 · Cited by 63
Optimizing drug discovery by Investigative Toxicology: Current and future trends
Beilmann, M., Boonen, H., Czich, A., Dear, G., Hewitt, P., Mow, T., Newham, P., Oinonen, T., Pognan, F., Roth, A., et al. (2018) · ALTEX · doi:10.14573/altex.1808181 · Cited by 85
“Significant human ADRs are predominantly associated with liver, heart, and neurological organs (Cook et al., 2014; Olson et al., 2000; Sacks et al., 2014).”
BackgroundMarone, G., Galdiero, M. R., Pecoraro, A., Pucino, V., Criscuolo, G., Triassi, M., & Varricchi, G. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1555237 · Cited by 62
“patients with moderate-to-severe asthma stabilized on ICS and long-acting β2-adrenergic receptor agonists failed to meet the primary endpoint and it was discontinued [119].”
Background3D human liver spheroids for translational pharmacology and toxicology
Ingelman‐Sundberg, M., & Lauschke, V. M. (2022) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13587 · Cited by 62
Biomarker-guided decision making in clinical drug development for neurodegenerative disorders
Cummings, J. L., Teunissen, C. E., Fiske, B. K., Ber, I. L., Wildsmith, K. R., Schöll, M., Dunn, B., & Scheltens, P. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01165-w · Cited by 87
Careers in nanomedicine and drug delivery
Nance, E. A. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.06.009 · Cited by 68
Decision‐making in early clinical drug development
Frewer, P., Mitchell, P., Watkins, C. L., & Matcham, J. (2016) · Pharmaceutical Statistics · doi:10.1002/pst.1746 · Cited by 60
“The need for scientific rigour in credentialing new product candidates at AstraZeneca has been identified [4] using the 5R framework, that is, identifying the right target, right tissue, right safety, right patients and right product potential.”
BackgroundGoh, J.-Y., Weaver, R. J., Dixon, L., Platt, N. J., & Roberts, R. A. (2015) · Toxicology Research · doi:10.1039/c5tx00123d · Cited by 60
“…the reliability of in silico testing to predict safety signals remains in its infancy and has even been called into question in a recent paper from Cook et al. (2014).20 Many of the tests reported in this study reduce and refine animal use by allowing early high throughput screening of compounds,…”
BackgroundDi Salvo, J., Nagabukuro, H., Wickham, L. A., Abbadie, C., DeMartino, J. A., Fitzmaurice, A., Gichuru, L., Kulick, A., Donnelly, M. J., Jochnowitz, N., et al. (2017) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.237313 · Cited by 58
“We also demonstrated that circulating glycerol and free fatty acid levels could potentially be used as surrogate pharmacodynamic readouts to predict bladder effects of vibegron, although care must be exercised when comparing pharmacodynamic effects in different tissue beds (Morgan et al., 2012; Cook et al., 2014).”
BackgroundClinical Trials in a Dish: A Perspective on the Coming Revolution in Drug Development
Fermini, B., Coyne, S. T., & Coyne, K. P. (2018) · SLAS DISCOVERY · doi:10.1177/2472555218775028 · Cited by 67
Long Circulating liposomes: Challenges and Opportunities
Deodhar, S., & Dash, A. K. (2018) · Therapeutic Delivery · doi:10.4155/tde-2018-0035 · Cited by 62
Introduction to precision medicine in COPD
Leung, J. M., Obeidat, M., Sadatsafavi, M., & Sin, D. D. (2019) · European Respiratory Journal · doi:10.1183/13993003.02460-2018 · Cited by 60
Drug repurposing: Clinical practices and regulatory pathways
Saranraj, K., & Kiran, P. U. (2024) · Perspectives in Clinical Research · doi:10.4103/picr.picr_70_24 · Cited by 72
“[28] Navigating regulatory pathways for repurposed drugs can be complex and time-consuming.”
Roberts, R. A., Aschner, M., Calligaro, D. O., Guilarte, T. R., Hanig, J. P., Herr, D. W., Hudzik, T. J., Jeromin, A., Kallman, M. J., Liachenko, S. M., et al. (2015) · Toxicological Sciences · doi:10.1093/toxsci/kfv188 · Cited by 58
“The ability to reliably identify neurotoxicity in preclinical animal models has been a challenge, especially during drug development, where central nervous system (CNS) toxicity is a major contributor to drug failure (Cook et al., 2014).”
BackgroundComputer-Aided Drug Design: An Overview
Talevi, A. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7756-7_1 · Cited by 70
Van Vleet, T. R., Liguori, M. J., Lynch, III, Rao, M., & Warder, S. (2019) · SLAS Discovery · doi:10.1177/2472555218799713 · Cited by 59
Paradigms for Precision Medicine in Epichaperome Cancer Therapy
Pillarsetty, N., Jhaveri, K. L., Taldone, T., Caldas-Lopes, E., Punzalan, B. J., Joshi, S., Bolaender, A., Uddin, M. M., Rodina, A., Yan, P., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.09.007 · Cited by 60
“Other studies have echoed these findings (Cook et al., 2014; Dolgos et al., 2016).”
Recent advances in human respiratory epithelium models for drug discovery
Yaqub, N., Wayne, G. J., Birchall, M., & Song, W. (2021) · Biotechnology Advances · doi:10.1016/j.biotechadv.2021.107832 · Cited by 67
Back to the future: re-establishing guinea pig in vivo asthma models
Adner, M., Canning, B. J., Meurs, H., Ford, W. R., Ramos‐Ramírez, P., van den Berg, M. P. M., Birrell, M. A., Stoffels, E., Lundblad, L. K. A., Nilsson, G. P., et al. (2020) · Clinical Science · doi:10.1042/cs20200394 · Cited by 60
Near‐Infrared Chemiluminescence Imaging of Chemotherapy‐Induced Peripheral Neuropathy
Liu, J., Huang, J., Wei, X., Cheng, P., & Pu, K. (2023) · Advanced Materials · doi:10.1002/adma.202310605 · Cited by 60
The state of the art in secondary pharmacology and its impact on the safety of new medicines
Brennan, R., Jenkinson, S. G., Brown, A. J., Delaunois, A. G., Dumotier, B. M., Pannirselvam, M., Rao, M., Ribeiro, L. R., Schmidt, F., Sibony, A., et al. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00942-3 · Cited by 69
Pioneering government-sponsored drug repositioning collaborations: progress and learning
Frail, D. E., Brady, M. C., Escott, K. J., Holt, A., Sanganee, H. J., Pangalos, M. N., Watkins, C. S., & Wegner, C. D. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4707 · Cited by 57
Self-citationTranslational Medicine Guide transforms drug development processes: the recent Merck experience
Dolgos, H., Trusheim, M. R., Groß, D., Halle, J.-P., Ogden, J., Osterwalder, B., Sedman, E., & Rossetti, L. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.01.003 · Cited by 58
Using What We Already Have: Uncovering New Drug Repurposing Strategies in Existing Omics Data
Pulley, J. M., Rhoads, J. P., Jerome, R. N., Challa, A. P., Erreger, K., Joly, M. M., Lavieri, R. R., Perry, K. E., Zaleski, N. M., Shirey-Rice, J. K., et al. (2019) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023537 · Cited by 64
Computer-Aided Drug Discovery and Design: Recent Advances and Future Prospects
Talevi, A. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3441-7_1 · Cited by 69
Can prospective systematic reviews of animal studies improve clinical translation?
Pound, P., & Ritskes-Hoitinga, M. J. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-019-02205-x · Cited by 60
Rodrigues, D., de Souza, T. M., Coyle, L., Piazza, M., Herpers, B., Ferreira, S., Zhang, M., Vappiani, J., Sévin, D. C., Gábor, A., et al. (2021) · Archives of Toxicology · doi:10.1007/s00204-021-03092-2 · Cited by 61
“Gastro-intestinal safety and toxicological assessment during development of drugs conventionally relies on experiments with animal models to investigate molecular mechanisms and biomarkers that are related to acute or chronic toxicity (Cook et al. 2014).”
BackgroundYouhanna, S. C., Kemas, A. M., Preiss, L. C., Zhou, Y., Shen, J. X., Cakal, S. D., Paqualini, F. S., Goparaju, S. K., Shafagh, R. Z., Lind, J. U., et al. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000238 · Cited by 67
Insights into the use of biomarkers in clinical trials in Alzheimer's disease
Pascoal, T. A., Aguzzoli, C. S., Lussier, F. Z., Crivelli, L., Suemoto, C. K., Fortea, J., Rosa‐Neto, P., Zimmer, E. R., Ferreira, P. C. L., & Bellaver, B. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105322 · Cited by 66
“65,74,75 Notably, the fact that the progression of A β and tau proteins occurs across different pathophysiological species, from oligomers to aggregates, 76,77 imposes an additional layer of complexity in ascertaining target engagement in AD.”
Timelines of translational science: From technology initiation to FDA approval
McNamee, L. M., Walsh, M. J., & Ledley, F. D. (2017) · PLOS ONE · doi:10.1371/journal.pone.0177371 · Cited by 54
“More research is required to fully understand how the maturity of the target technology, the maturation of technologies related to the chemical entity, and other information known to be associated drug development such as Lipinski’s “rule of 5” [30] and AstraZeneca’s “5 R’s” [31],collectively contribute to the probabi…”
BackgroundRecent Progress in European Advanced Therapy Medicinal Products and Beyond
Yu, T. T. L., Gupta, P., Ronfard, V., Vertès, A. A., & Bayon, Y. (2018) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2018.00130 · Cited by 60
“Symbolized as “the five R’s,” this concept incorporates notions regarding the right target, the right tissue, the right safety, the right patients and the right commercial potential (Cook et al., 2014), which can be carefully considered before committing and investing several billion dollars for a more than decade-lon…”
BackgroundVasile, C. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813932-5.00001-7 · Cited by 57
Tukker, A. M., Wijnolts, F. M. J., de Groot, A., & Westerink, R. H. S. (2020) · Toxicological Sciences · doi:10.1093/toxsci/kfaa136 · Cited by 56
Dunlop, J., & Brandon, N. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565806 · Cited by 63
“Interestingly this trial was recently highlighted in a review published by AstraZeneca on lessons learnt from recent drug discovery efforts and it was suggested that in this trial insufficient exposure of the drug was responsible for the result (Cook et al., 2014).”
BackgroundKell, D. B. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.10.005 · Cited by 58
Drug discovery and development: Biomarkers of neurotoxicity and neurodegeneration
Walker, A. L., Imam, S. Z., & Roberts, R. A. (2018) · Experimental Biology and Medicine · doi:10.1177/1535370218801309 · Cited by 59
“For original data see Cook et al.(7)(A color version of this figure is available in the online journal.”
BackgroundTagle, D. A. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.09.007 · Cited by 68
Noor, H., Ikram, A., Rathinavel, T., Kumarasamy, S., Iqbal, M. N., & Bashir, Z. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1873190 · Cited by 56
“After validating good ligand – target complexes, it is necessary to check the ADME properties of a drug-like ligand compound, for sufficiently high quality to be developed into new medication (Bergstrom & Larsson, 2018; Cook et al., 2014 ).”
BackgroundJentzsch, V., Osipenko, L., Scannell, J. W., & Hickman, J. A. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.24977 · Cited by 56
McNulty, D. E., Bonnette, W. G., Qi, H., Wang, L., Ho, T. F., Waszkiewicz, A., Kallal, L. A., Nagarajan, R. P., Stern, M., Quinn, A. M., et al. (2017) · SLAS DISCOVERY · doi:10.1177/2472555217732014 · Cited by 52
Production of cocrystals in an excipient matrix by spray drying
Walsh, D. P., Serrano, D. R., Worku, Z. A., Norris, B. A., & Healy, A. M. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.12.020 · Cited by 54
Tissue-specific genes as an underutilized resource in drug discovery
Ryaboshapkina, M., & Hammar, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-43829-9 · Cited by 61
Smith, M. M., Clarke, E., & Little, C. B. (2016) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2016.10.016 · Cited by 55
Boger, E., & Fridén, M. (2018) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2017.1436 · Cited by 56
“(30,31) In addition to functional readouts in preclinical studies that suggest that a localized exposure has been achieved, PBPK modeling could provide further clarity and underpinning of the prediction of therapeutic dosing in humans.”
Belair, D. G., Visconti, R. J., Hong, M., Marella, M., Peters, M. F., Scott, C. W., & Kolaja, K. L. (2020) · Toxicology in Vitro · doi:10.1016/j.tiv.2020.104928 · Cited by 54
Zhang, H., Ren, J.-X., Ma, J., & Ding, L. (2018) · Molecular Diversity · doi:10.1007/s11030-018-9882-8 · Cited by 52
Why is it hard to terminate failing projects in pharmaceutical R&D?
Peck, R., Lendrem, D. W., Grant, I., Lendrem, C., & Isaacs, J. D. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4725 · Cited by 55
Managing risks in drug discovery: reproducibility of published findings
Kannt, A., & Wieland, T. (2016) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-016-1216-8 · Cited by 57
“Previously, drug discovery was a process-driven and technology-oriented, almost factory-like high-throughput approach starting with a gene regulated in an animal model of disease (or the parallel interrogation of many disease-related genes) via the identification and optimization of compounds to their characterization…”
BackgroundInfluentialYamamoto, Y., Danhof, M., & de Lange, E. C. M. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0050-3 · Cited by 56
“And around 50% of the attrition of potential CNS drugs has resulted due to a lack of efficacy and safety issues in phase 2 (2, 3).”
BackgroundBritton, O. J., Abi‐Gerges, N., Page, G., Ghetti, A., Miller, P. E., & Rodríguez, B. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00597 · Cited by 52
“The current difficulty of predicting cardiotoxic effects of new drug candidates plays a major role in the termination of drug development programmes (Cook et al., 2014).”
BackgroundSingle cell RNA sequencing of stem cell-derived retinal ganglion cells
Daniszewski, M., Senabouth, A., Nguyen, Q. H., Crombie, D. E., Lukowski, S. W., Kulkarni, T., Sluch, V. M., Jabbari, J. S., Chamling, X., Zack, D. J., et al. (2018) · Scientific Data · doi:10.1038/sdata.2018.13 · Cited by 51
Drug tolerance: a known unknown in translational neuroscience
Bespalov, A., Müller, R., Relo, A.-L., & Hudzik, T. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.01.008 · Cited by 50
Shao, W., Xu, H., Zeng, K., Ye, M., Pei, R., & Wang, K. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04139-2 · Cited by 63
Target Engagement Assays in Early Drug Discovery
John‐Campbell, S. S., & Bhalay, G. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c03115 · Cited by 66
England, R., Hare, J. I., Barnes, J., Wilson, J., Smith, A., Strittmatter, N., Kemmitt, P. D., Waring, M. J., Barry, S. T., Alexander, C., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.12.034 · Cited by 51
“One of the key considerations for cancer medicines remains establishing a therapeutic index [1], since targeting key cellular processes can induce significant toxicity, and therapeutic margins are typically”
Pridgeon, C. S., Schlott, C., Wong, M. W., Heringa, M. B., Heckel, T., Leedale, J., Launay, L., Gryshkova, V., Przyborski, S. A., Bearon, R. N., et al. (2018) · Archives of Toxicology · doi:10.1007/s00204-018-2152-9 · Cited by 55
“Indicated are the major organ systems involved in pre-clinical and clinical safety failures (Cook et al. 2014) as well as opportunities for the application of 3D or organotypic in vitro models.”
BackgroundRodriguez, B., Carusi, A., Abi-Gerges, N., Ariga, R., Britton, O., Bub, G., Bueno-Orovio, A., Burton, R. A. B., Carapella, V., Cardone-Noott, L., et al. (2016) · Europace · doi:10.1093/europace/euv320 · Cited by 49
Shen, J. X., Youhanna, S., Zandi Shafagh, R., Kele, J., & Lauschke, V. M. (2020) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00245 · Cited by 49
CETSA: A Target Engagement Assay with Potential to Transform Drug Discovery
Jensen, A. J., Molina, D. M., & Lundbäck, T. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.50 · Cited by 49
Reverse translation of adverse event reports paves the way for de-risking preclinical off-targets
Maciejewski, M., Lounkine, E., Whitebread, S., Farmer, P. J., DuMouchel, W., Shoichet, B. K., & Urbán, L. (2017) · eLife · doi:10.7554/elife.25818 · Cited by 50
“Pre-clinical regulatory investigations and clinical trials are designed to address safety of drug candidates and eliminate those that do not meet risk-benefit expectations ( Cook et al., 2014 ).”
BackgroundZafar, S., Beg, S., Panda, S. K., Rahman, M., Alharbi, K. S., Jain, G. K., & Ahmad, F. J. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.08.023 · Cited by 51
Brasier, A. R., & Zhou, J. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.11.002 · Cited by 48
Advanced Fabrication Techniques of Microengineered Physiological Systems
Puryear, J. R., Yoon, J., & Kim, Y. (2020) · Micromachines · doi:10.3390/mi11080730 · Cited by 56
Lin, Z., Zou, J., Liu, S., Peng, C., Li, Z., Wan, X., Dong, F., Yin, J., Gobbo, G., Chen, Y., et al. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c01329 · Cited by 55
Drug toxicity in the proximal tubule: new models, methods and mechanisms
Hall, A. M., Trepiccione, F., & Unwin, R. J. (2021) · Pediatric Nephrology · doi:10.1007/s00467-021-05121-9 · Cited by 54
Witkin, J. M., LIPPA, A. S., Smith, J. L., Jin, X., Ping, X., Biggerstaff, A., Kivell, B. M., Knutson, D. E., Sharmin, D., Pandey, K. P., et al. (2022) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2021.173321 · Cited by 51
Kiani, Y. S., & Jabeen, I. (2019) · ACS Omega · doi:10.1021/acsomega.9b02344 · Cited by 56
Network integration and modelling of dynamic drug responses at multi-omics levels
Selevsek, N., Caiment, F., Nudischer, R., Gmuender, H., Agarkova, I., Atkinson, F. L., Bachmann, I., Baier, V., Barel, G., Bauer, C., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-01302-8 · Cited by 55
The Drug Discovery and Development Industry in India—Two Decades of Proprietary Small‐Molecule R&D
Differding, E. (2017) · ChemMedChem · doi:10.1002/cmdc.201700043 · Cited by 53
Butler, L. D., Guzzie‐Peck, P., Hartke, J., Bogdanffy, M. S., Will, Y., Diaz, D., Mortimer‐Cassen, E., Derzi, M., Greene, N., & DeGeorge, J. J. (2017) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2017.05.009 · Cited by 51
Jiang, S., Xu, F., Jin, M., Wang, Z., Xu, X., Zhou, Y., Wang, J., Gu, L., Han, F., Fan, Y., et al. (2022) · Biofabrication · doi:10.1088/1758-5090/ac933c · Cited by 55
Cell- and biomarker-based assays for predicting nephrotoxicity
Huang, J. X., Blaskovich, M. A., & Cooper, M. A. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.967681 · Cited by 46
“Similarly, 52% of projects failed in the clinical phase due to safety, with 9% due to renal issues [8].”
BackgroundClinical protein science in translational medicine targeting malignant melanoma
Gil, J., Betancourt, L. H., Pla, I., Sanchez, A., Appelqvist, R., Miliotis, T., Kuras, M., Oskolas, H., Kim, Y., Horvath, Z., et al. (2019) · Cell Biology and Toxicology · doi:10.1007/s10565-019-09468-6 · Cited by 45
Puratchikody, A., Sriram, D., Umamaheswari, A., & Navabshan, I. (2016) · Chemistry Central Journal · doi:10.1186/s13065-016-0169-9 · Cited by 56
“Toxicity study ADMET descriptors Most of the failure of drug candidates during clinical trials is due to its poor pharmacokinetic and toxicity properties [13].”
BackgroundPerspective on CETSA Literature: Toward More Quantitative Data Interpretation
Seashore-Ludlow, B. A., Axelsson, H., & Lundbäck, T. (2019) · SLAS DISCOVERY · doi:10.1177/2472555219884524 · Cited by 45
Hanapi, N. A., Mohamad Arshad, A. S., Abdullah, J. M., Tengku Muhammad, T. S., & Yusof, S. R. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.09.015 · Cited by 45
Metadata
- Authors
- Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N.
- Affiliations
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Pangalos, Menelas N.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-05-16
- Volume
- 13
- Issue
- 6
- Pages
- 419-431
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1967105697
- Cited by
- 1,344
- References
- 75
- Citations by year
- 2026: 90 · 2025: 92 · 2024: 104 · 2023: 110 · 2022: 99 · 2021: 123 · 2020: 118 · 2019: 125 · 2018: 131 · 2017: 115 · 2016: 124 · 2015: 92 · 2014: 20
- FWCI
- 33.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Keywords
- AstraZeneca, drug development pipeline, small molecule drug development, R&D productivity, project success factors, target selection, patient selection, tissue selection, drug safety, business potential, organizational culture, pharmaceutical industry
- MeSH terms
- Animals, Clinical Trials as Topic, Decision Making, Organizational, Drug Industry, Drug Evaluation, Preclinical, Humans, Research Support as Topic, Technology, Pharmaceutical, Drug Design, Organizational Culture, Drugs, Investigational, Models, Organizational, Efficiency, Organizational, Biomedical Research, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.